ZZPZH(SH:600436)2018-02-06 16:00Financial Performance - Total operating revenue for 2017 reached RMB 372,717.55 million, a year-on-year increase of 61.42%[2] - Operating profit increased by 49.56% to RMB 91,007.22 million, while total profit rose by 50.58% to RMB 91,737.79 million[2] - Net profit attributable to shareholders was RMB 79,055.17 million, reflecting a growth of 47.45% compared to the previous year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 45.73% to RMB 76,131.76 million[2] - Basic earnings per share rose by 47.19% to RMB 1.31[2] Assets and Equity - Total assets at the end of the reporting period were RMB 560,696.80 million, an increase of 11.30% from the beginning of the period[3] - Shareholders' equity attributable to the parent company increased by 17.96% to RMB 412,075.35 million[3] Revenue Drivers - The increase in revenue was primarily driven by sales growth of the main product series, with additional revenue of RMB 1,071 million from the subsidiary Xiamen Pianzaihuang Hongren Pharmaceutical Co., Ltd.[4] Non-recurring Items - Non-recurring gains and losses increased by 112.88%, mainly due to the disposal of shares in Fujian Taier Technology Co., Ltd., impacting the current period's profit by approximately RMB 21.32 million[4] Cautionary Note - The company warns that the financial data for 2017 is preliminary and has not been audited, urging investors to be cautious[6]